STAT3 activation in monocytes accelerates liver cancer progression by Wu, Wen-Yong et al.
RESEARCH ARTICLE Open Access
STAT3 activation in monocytes accelerates liver
cancer progression
Wen-Yong Wu
1, Jun Li
2*, Zheng-Sheng Wu
3, Chang-Le Zhang
1 and Xiang-Ling Meng
1
Abstract
Background: Signal transducer and activator of transcription 3 (STAT3) is an important transcription factor
ubiquitously expressed in different cell types. STAT3 plays an essential role in cell survival, proliferation, and
differentiation. Aberrantly hyper-activated STAT3 signaling in cancer cells and in the tumor microenvironment has
been detected in a wide variety of human cancers and is considered an important factor for cancer initiation,
development, and progression. However, the role of STAT3 activation in monocytes in the development of HCC
has not been well understood.
Methods: Immunohistochemical analysis of phosphorylated STAT3 was performed on tissue microarray from HCC
patients. Using a co-culture system in vivo, HCC cell growth was determined by the MTT assay. In vivo experiments
were conducted with mice given diethylinitrosamine (DEN), which induces HCC was used to investigate the role of
STAT3 expression in monocytes on tumor growth. Real-time PCR was used to determine the expression of cell
proliferation and cell arrest associated genes in the tumor and nontumor tissue from liver.
Results: Phosphorylated STAT3 was found in human hepatocellular carcinoma tissue samples and was expressed
in tumor cells and also in monocytes. Phosphorylated STAT3 expression in monocyte was significantly correlated to
advanced clinical stage of HCC and a poor prognosis. Using a co-culture system in vivo, monocytes promoted HCC
cell growth via the IL-6/STAT3 signaling pathway. The STAT3 inhibitor, NSC 74859, significantly suppressed tumor
growth in vivo in mice with diethylinitrosamine (DEN)-induced HCC. In this animal model, blockade of STAT3 with
NSC 74859 induced tumor cell apoptosis, while inhibiting both tumor cells and monocytes proliferation.
Furthermore, NSC 74859 treatment suppressed cancer associated inflammation in DEN-induce HCC.
Conclusion: Our data suggest constitutively activated STAT3 monocytes promote liver tumorigenesis in clinical
patients and animal experiments. Thus, STAT3 in tumor infiltrating inflammatory cells may an attractive target for
liver cancer therapy.
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Background
A causal link between chronic inflammation and the
development of cancer has long been recognized from
clinical and animal investigations and has become an issue
of high interest in recent years [1]. Although it is well
accepted that chronic inflammation can affect all phases of
carcinogenesis, from the initial cancer formation by indu-
cing genetic alteration, to the subsequent cancer formation
by establishing an inflammatory environment that allows
tumors to grow, metastasize and escape the host anti-
tumor immune response [1,2], the exact mechanisms of
inflammation favoring carcinogenesis are largely currently
unknown. The interplay between chronic inflammation
and cancer is very complex. Previous reviews have already
demonstrate this interesting issue in detail [1,2]. Briefly,
chronic inflammation and incomplete repair can hasten
the oncogenic processes by directly promoting genetic
instability and favoring the induction of gene mutation. It
is believed abundant reactive oxygen (ROS) produced by
inflammatory cells can induce DNA damage, mutations
and genetic instability. Secondly, many well known onco-
genic genes including RAS, RET, BRAF and MYC appear
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any medium, provided the original work is properly cited.to play a role in inflammation as well [3]. These oncogenes
turn on the inflammatory pathway within a cell, activate
inflammation outside the cell to recruit inflammatory cells
leading to an immuno-suppressive tumor microenviron-
ment [2,4,5]. Lastly, many transcription factors such as
NF-B, STAT3 and the adaptor protein MyD88, which
are all key to the innate inflammatory response, are also
essential in certain kinds of cancers [6-9].
Constitutively activated IL-6/STAT3 signaling has been
detected in a wide variety of human cancers including
liver cancer and is considered an important factor for can-
cer initiation, development, and progression [7,10-12].
Hepatocellular carcinoma (HCC) is the most common pri-
mary malignancy in liver and the third leading cause of
cancer deaths worldwide, with few effective therapeutic
options for this severe disease [13-15]. Most HCC appears
in cirrhotic livers after years of chronic liver inflammation
caused by hepatitis viral infection, alcoholic and non-alco-
holic steatohepatitis [14,16]. Various factors can active
hepatic STAT3 signaling such as inflammatory cytokines,
growth factors, hormones, and hepatitis viral proteins [17].
Several cytokines (such as IL-6, IL-6 family cytokines and
IL-22) that activate STAT3 in hepatocytes have been
shown to promote HCC cell growth in vivo and in vivo
[18,19]. Recently, Park et al. reported that localized pro-
duction of IL-22 in the liver promotes hepatocyte survival
and proliferation, thereby accelerating the HCC develop-
ment after DEN challenge [20]. Moreover, emerging evi-
dence suggests that the cytokines downstream of STAT3
play an important role in the development of liver cancer
[21-23]. Blockage of STAT3 may have therapeutic poten-
tial in preventing and treating liver cancer [24-26]. Our
previous study on HCC specimens suggests an oncogenic
role of STAT3 in liver cancer. In the previous study tumor
expression of STAT3 was correlated with disease progres-
sion and poor survival rates [27]. In the present study we
further investigate whether monocyte expression of
STAT3 in the tumor microenvironment could promote
tumor growth and whether the STAT3 inhibitor, NSC
74859, can prevent diethylinitrosamine (DEN)-induced
HCC by suppressing STAT3 activation and its associated
inflammation.
Methods
Cancer specimens
A total of 138 HCC patients were enrolled in this study
with an informed patient consent following the human
study protocol approved by the Anhui Medical University
Ethics Committee. Formalin-fixed and paraffin-embedded
HCC and normal liver specimens were obtained from the
Department of Pathology within the First Affiliated Hospi-
tal of Anhui Medical University, P.R. China. All HCC sam-
ples were collected from patients with varying grades and
stages of cancer. Two independent pathologists evaluated
blinded tumors samples used in this study. All the hema-
toxylin and eosin-stained sections from each paraffin-
embedded, formalin-fixed block were reviewed to identify
target areas.
Tissue microarrays (TMA) construction
Paraffin-embedded tumor specimens were obtained from
an archive of the Department of Pathology within the First
Affiliated Hospital of Anhui Medical University, P.R.
China. TMAs were constructed as previously described
[27]. Three to five representative 1 mm cores were
obtained from each case and inserted in a grid pattern
into a recipient paraffin block (Hengtai Instruments Inc.,
Liaoning, P.R. China).
Immunohistochemistry staining
TMA sections of HCC were stained through immunohis-
tochemistry using primary antibodies against
pY705STAT3
(Cell Signaling Technology, Danvers, MA, USA). The fre-
quency of p
Y705STAT3-positive cells was measured by
counting the total number of cells and the number of
positively stained cells. More than 25% nuclear staining
was classified as positive.
For cell proliferation Ki67 staining, the sections were
stained in accordance with routine immunohistochemistry
procedures and visulaized with the ABC kit (Vector
Laboratories, Burlingame, CA, USA). Biotinylated rat anti-
mice Ki67 antibody at 1:100 dilution was used. Hepatocyte
or tumor cell apoptosis was detected by using an Apoptag
Apoptosis Detection Kit (Chemicon International, Teme-
cula, CA, USA).
Co-culture of monocytes and HCC cells
The HCC cell lines HepG2 and Huh-7 were obtained from
the Shanghai cell bank, Chinese Academy of Sciences,
Shanghai, China. These two cell lines were maintained in
Dulbecco’sM o d i f i e dE a g l e ’s Medium (DMEM). Both types
of medium were supplemented with 10% fetal bovine
serum.
PBMCs from health subjects were freshly isolated by
gradient centrifugation from discarded leukocyte filters
obtained during platelet collection from healthy adults at
the First Affiliated Hospital of Anhui Medical University.
Monocytes were isolated by negative selection using Dynal
Monocyte Negative Isolation Kit (Invitrogen) according to
the manufacturer’s instructions. All in vivo experiments
were performed in Ultra Low Attachment Plates (Corning)
to prevent monocyte activation by adhesion to the plastic
plate. In co-culture experiments, freshly isolated mono-
cytes (5 × 10
6) were added to the inserts separated by 0.4-
μm membrane (Costar; Corning) from HCC cells. For the
cell proliferation analysis, HCC cell line HepG2 or Huh-7
were co-cultured with or without moncytes for 48 h and
the MTT assay was performed as described below.
Wu et al. BMC Cancer 2011, 11:506
http://www.biomedcentral.com/1471-2407/11/506
Page 2 of 103-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay
The MTT assay is based on the conversion of the yellow
tetrazolium salt MTT to purple formazan crystals by
metabolically active cells. The MTT assay provides a
quantitative determination of viable cells. Cells (1 × 10
4)
were seeded in 96-well microplates in complete culture
medium in the absence or presence of anti-IL-6 antibody
or NSC 74859 as indicated. After 72 h of culturing, the
number of viable cells was measured by adding 100 μl/
well of 2 mg/ml MTT solution. The medium was removed
2 h later and the formazan crystals were dissolved by add-
ing 100 μl dimethylsulfoxide per well. The absorbance was
read at 590 nm with an enzyme-linked immunosorbent
assay reader. Each treatment point was performed with an
n=6 .
Mice and diethylnitrosamine (DEN)-induced liver cancer
model
All experiments with mice were approved by Anhui Medi-
cal University Animal Care and Use Committee. C57BL/6
mice were obtained from Animal Center of Anhui Medical
University. Mice were kept in pathogen-free conditions
with room temperature of (23 ± 2C), humidity (55-60%),
and light conditions (12 h light/dark cycle).
The DEN-induced liver tumor model in mice was estab-
lished as described previously [28,29]. Briefly, 15-day-old
B6 mice were injected with 5 μg/g DEN (Sigma, St. Louis,
MO). Six months after the injection series with normal
chow, all the mice were randomly separated into two
groups; the NSC 74859 group or vehicle only group. Mice
were then injected intraperitoneally with 5 mg/kg NSC
74859 twice per week for 3 months prior to sacrifice at 9
months after DEN injection. Livers were removed and the
tumor numbers and sizes were analyzed. Histological sec-
tions were taken including larger tumor nodules that were
fixed in 10% formalin. Hematoxylin-eosin (H&E) staining
was performed using standard protocols. The liver tumor
tissues and nontumor tissues were carefully separated and
frozen in liquid nitrogen for subsequently real-time PCR
determination.
For liver tumor analysis, the whole liver was carefully
removed from the euthanized animal, washed and placed
in cold PBS. The numbers of surface liver tumor nodules
were counted for all liver lobes in a blinded fashion. Liver
nodules typically presenteda sb a s o p h i l i cf o c iw i t h
crowded nuclei and were classified as atypical foci (HCC)
or hepatocellular adenomas.
Real-time PCR
Real-time PCR was used to determine the expression of
cell proliferation and cell arrest associated genes in the
tumor and nontumor tissues from liver samples. Total
RNA was purified from approximately 30 mg of liver
tumor or nontumor samples according to the manufac-
turer instruction (Qiagen). 1 μg of mRNA was reverse-
transcribed to cDNA using a High Capacity cDNA
Reverse Transcription kit (Invitrogen). cDNA templates
were diluted 1:5 and amplified using real-time PCR
through the iTaq SYBR Green Supermix (Bio-Rad, Her-
cules CA). An initial denaturation at 95°C for 3 min was
followed with PCR cycling: 95°C (15 sec), and 58°C (30
sec) for 40 cycles. Relative mRNA levels were calculated
by means of 2
- ΔΔ Ct (ΔΔ Ct = difference of crossing
points of test samples and respective control samples as
extracted from amplification curves by the LightCycler
software) after normalization to 18S rRNA expression,
which was used as an internal standard. Fold inductions
of analyzed mRNA expression were normalized on 18S
rRNA expression. PCR was performed with 12.5 μl SYBR
Master Mixture and the following primers in Table 1.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware system for Windows (version 13.0; SPSS, Chicago,
IL, USA). Differences between groups were compared
using Pearson’s chi-square test for qualitative variables
and Student’s t-test for continuous variables. Kaplan-
Meier curves were constructed to determine patient
relapse-free survival (RFS) and overall survival (OS) rates.
The statistical differences in survival among subgroups
were compared using the log-rank test. Data of HCC mice
model were expressed as means ± SE (N = 4-8 in each
group). To compare values obtained from three or more
groups, 1-factor analysis of variance (ANOVA) was used,
followed by Tukey’s post hoc test. P < 0.05 was considered
statistically significant. The correlations between variables
were assessed by the Spearman rank order test. Statistical
significance was taken at the P < 0.05 level.
Results
Phosphorylated STAT3 in hepatocellular carcinoma tissue
is not only expressed on tumor cells, but also on
monocytes
Previous study have shown that STAT3 and pSTAT3
expression is dramatically increased in HCC tissues when
compared with normal liver samples [22]. To further
Table 1 Primer sequences for real-time PCR
genes Forward primer (5’...3’) Reverse primer (5’...3’)
TNF-a AAGCCTGTAGCCCACGTCGTA AGGTACAACCCATCGGCTGG
IL-1b AAAAAAGCCTCGTGCTGTCG GTCGTTGCTTGGTTCTCCTTG
IL-6 TCCATCCAGTTGCCTTCTTG TTCCACGATTTCCCAGAGAAC
MCP-1 TCAGCCAGATGCAGTTAACGC TCTGGACCCATTCCTTCTTGG
IFN-g GCCCTCTCTGGCTGTTACTG CTGATGGCCTGGTTGTCTTT
18 s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
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were responsible for pSTAT3 activation and the STAT3
signaling and whether this signaling pathway was corre-
lated with the prognosis of HCC patients, we initially
used immunohistochemistry to analyze pSTAT3 expres-
sion in HCC tissues and its association with patient’s
clinicopathological parameters (Table 2). Positive
pSTAT3 staining in monocytes and overall survival was
evaluated using Kaplan-Meier survival curves and the
log-rank test (Figure 1b). After reviewing the TMA slides
of HCC, we found 113 out of 138 HCC cases had the
inflammation cells infiltration. Among the 113 patients
studied, 92 patients were classified as HBsAg positive and
101 patients were classified as cirrhosis patients. In the
non-peritumoral area in tumors from these patients, the
inflammatory cell infiltration was generally dense, as seen
in the cirrhotic stroma, and several pSTAT3 positive
monocytes were detected (not taken into account in the
evaluation). To clarify the interaction between the mono-
cytes and tumor cells in the tumor microenvironment,
pSTAT3 expression was investigated in the limited areas
of the peritumoral and the intratumoral area. As shown
in Table 3, a statistically significant difference of pSTAT3
was observed in tumor cells (54.3%) and monocytes
(60.2%) when compared with adjacent non-tumorous
tissue. As shown in Table 4, a statistically significant cor-
relation was seen between pSTAT3 expression in tumor
cells and its adjacent pSTAT3 positive monocytes by
Spearman correlation analysis(P < 0.001, rs = 0.440). For
the non-tumoral liver tissue (tissue away from the peritu-
moral and intratumoral area), the pSTAT3 expression
was weak or scarce except for the inflammatory foci area.
These data are summarized in Tables 2, 3 and 4. Interest-
ingly, expression of pSTAT3 in monocytes was increased
in intratumoral tissues compred to adjacent peritumoral
tissues (Figure 1a). Monocyte expression of pSTAT3 was
significantly correlated to higher clinical stages of HCC
(P = 0.032, Table 1). Next, we further identify the correla-
tion of pSTAT3 expression in monocytes with the prog-
nosis of HCC inpatients. As shown in Figure 1b, HCC
patients with enhanced pSTAT3 expression in monocytes
had a significantly worse OS and RFS after curative
Table 2 Correlation of pSTAT3 expression in moncytes
with clinicopathological parameters from HCC patients
(n = 113)
Parameter n pSTAT3 positive expression, n (%) p value
Age (years)
≤ 55 67 45 (67.2) 0.067
> 55 46 23 (50.0)
Gender
Male 93 55 (59.1) 0.627
Female 20 13 (65.0)
Cirrhosis
Yes 101 63 (62.4) 0.166
No 12 5 (41.7)
HBsAg
Yes 92 58 (63.0) 0.193
No 21 10 (47.6)
Tumor size (cm)
< 5 32 17 (53.1) 0.336
≥ 5 81 51 (63.0)
Grade
I 4 2 (50.0) 0.472
II 107 64 (59.8)
III 2 2 (100.0)
Stage
I-II 86 47 (54.7) 0.032
III-IV 27 21 (77.8)
Ki67
< 50% 45 24 (53.3) 0.227
≥ 50% 68 44 (64.7)
Figure 1 S T A T 3a c t i v a t i o ni nm o n o c y t e si nH C Cp a t i e n t s .( a)
Representative images of pSTAT3 immunostaining in intratumoral
(left) and adjacent peritumoral (right) tissues are shown. (b) Overall
survival and relapse-free survival for HCC patients according to
presence of pSTAT3 expression in monocytes.
Table 3 Expression of pSTAT3 in HCC and adjacent
non-tumour tissue specimens
Group n Positive expression of pSTAT3 protein, n
tumor/liver cells n monocytes
HCC 138 75 (54.3)* 113 68 (60.2)*
Non-tumorous 110 35 (31.8) 110 27 (24.5)
*P < 0.001
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0.016 and 0.001, respectively).
Monocytes promote HCC cells growth via IL-6/STAT3
pathway
To further analyze the underlying mechanism of the poor
prognosis in HCC with increased expression of monocyte
STAT3, we cultured HCC cell lines HepG2 or Huh-7
alone, or co-cultured these cells using transwell chambers
with HCC cells in the presence of peripheral blood-
derived monocytes. As shown in Figure 2, cell proliferation
of HepG2 or Huh-7 was much higher in co-cultures of
both cell types for 24 hrs when compared with single cul-
ture of HCC cells. Pretreated with an IL-6 antibody or
STAT3 inhibitor significantly suppressed HCC cells
growth. Cell proliferation was comparable between HCC
cells only and tumor cells treated with or without IL-6
antibody or STAT3 inhibitor. These in vivo data clearly
show that activated STAT3 in monocytes can promote
cancer cells growth in a paracrine dependent manner.
Inhibition of STAT3 with NSC 74859 results in tumor
regression in DEN-induced HCC mouse model
Previous studies have shown that STAT3 inhibitors can
suppress tumor cell growth in vivo and tumor growth in a
tumor xenograft mouse model [22]. Here, using the tradi-
tional DEN-induced HCC model, we investigated the
effects of the STAT3 inhibitor, NSC 74859, on HCC
development. Both the control and the STAT3 inhibitor
treated mice (8 mice per group) were injected with DEN
at day 15. Both NSC 74859 and the vehicle alone were
injected intraperitoneally at 5 mg/kg twice per week for 3
months prior to sacrificing the mice at 9 months after
DEN injection. The numbers of surface liver tumor
nodules from all liver lobes were enumerated and the sizes
of the tumor nodules were also calculated. As illustrated
in Figure 3, injection of NSC 74859 inhibited tumor devel-
opment in the DEN-induced tumor model. The tumor
size and number were significantly smaller in NSC 74859
treated mice compared to wild-type mice after injection of
20 μg/g of DEN.
Histological analysis (Figure 3) shows that liver tumors
from both groups had a moderate degree of differentiation
with an increased nuclear-to-cytoplasmic index, enlarged
and hyperchromatic nuclei and expansive growth. In the
area of the tumor tissues, the normal liver architecuture,
such as bile duct and portal tract formation, was lost. Con-
sistent with the results in Figure 3a, the tumor size was
much smaller after NSC 74859 treatment. These data
clearly demonstrate the anti-tumor capacity of NSC 74859
in DEN-induce HCC development. Immunohistochemical
staining analysis also shows stronger pSTAT3 expression
in both tumor and inflammatory cells compared to the
vehicle control treatment mice, while NSC74859 markedly
decreased pSTAT3 expression (Figure 3). Hematoxylin
and eosin staining indicate a large inflammatory cell infil-
tration in DEN-treated mice, compared to vehicle control
mice. Inflammation reduced in the adjacent area to tumor
tissue after NSC 74859 therapy (Figure 3).
Blockade of STAT3 with NSC 74859 induced tumor cell
apoptosis, while inhibited both tumor cells and monocytes
proliferation in DEN-induced HCC mouse model
To explore the possible mechanisms underlying the
anti-tumor effects of the STAT3 inhibitor in this HCC
Table 4 Correlation analysis of pSTAT3 expression
between in tumor cell and monocyte in HCC
Monocyte expression of pSTAT3 Tumor cell expression of pSTAT3
Negative Positive
Negative 87 (68.0) 41 (32.0)
Positive 38 (40.0) 57 (60.0)
*P < 0.001, rs = 0.440
Figure 2 Monocytes promoted HCC cell proliferation in vitro
via IL-6/STAT3 signaling pathway.
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tumor tissue after DEN exposure in both groups. As
shown in Figure 4, administration of NSC 74859 led to
more apoptotic tumor cells and less Ki67
+ tumor cells.
Moreover, NSC 74859 also reduced the cancer-asso-
ciated inflammatory cell proliferation.
Constitutively activated STAT3 promotes tumorigen-
esis through the upregulation of cell cyclin related gene
[12,30-32]. Therefore, we compared the cell cyclin
related gene expression (Cyclin B1, Cyclin D, Cyclin E
and p21) between the NSC 74859 treatment and control
groups through real-time PCR. The expression of Cyclin
B1, Cyclin D and Cyclin E in NSC 74859 treated mice
were low compared with the untreated mice in both
tumor tissue and non-tumor tissue, as shown in Figure
5, which was correlated with the reduced proliferation
in the NSC 74859 treated group. In contrast, the level of
p21 was higher in NSC 74859 group compared with the
untreated controls.
NSC 74859 suppressed cancer associated inflammation in
DEN-induce HCC
Since a causal relationship between chronic injury and
inflammation and liver carcinogenesis in the majority of
HCC patients is well established, we wondered whether
the STAT3 inhibitor can also affect liver inflammation
in the DEN-induced HCC model. To test this possibility,
the mRNA expression of several pro-inflammatory
Figure 3 NSC 74859 reduced DEN-induced liver tumorigenesis (a)
The mice from control and NSC 74859 group treated with 5 μg/g
of DEN at age 15 days and sacrificed post-DEN (8 mice per
group). The number and size of tumors on surface were counted. (b)
Representative images of livers, H&E staining, inflammation and
pSTAT3 immunostaining are shown. T: tumor; NT: non-tumor tissues.
The arrows in inflammation analysis indicate the inflammatory foci.
Figure 4 NSC 74859 promoted tumor cell apoptosis while
inhibited tumor cell and monocytes proliferation
Representative images of TUNEL staining and Ki67
immunostaining are shown.
Figure 5 NSC 74859 regulated cell cyclin gene expression in
DEN-induced HCC mice. mRNA in T and NT tissues were analyzed
by real-time PCR (n = 4).
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of macrophages (F4/80) and monocytes (CCR2) were
examined using real-time PCR in mice with or without
NSC 74859 treatment. Interestingly, as illustrated in
Figure 6, both tumor and non tumor tissue after STAT3
inhibitor administration displayed less expression of
inflammatory cell marker and cytokines compared with
those in untreated tissue. Those data indicated the
STAT3 inhibitor also can reduce inflammation after
DEN challenge.
Discussion
Although transcription factors such as NF-Ba n d
STAT3, are key molecules implicated in cancer-related
inflammation [21-23,33-36], the current study provides
several novel findings demonstrating the importance of
monocytes STAT3 activation in facilitating HCC pro-
gress in human patients and in an animal model. First, a
negative correlation was observed between STAT3 acti-
vation in monocytes and overall survival in human HCC
patients. Second, in co-culture experiemtns with mono-
cytes and tumor cells, monocytes enhance HCC cell
proliferation, which was dependent on IL-6/STAT3 sig-
naling pathway. And finally, STAT3 inhibitor treatment
in DEN-induced HCC animal not only reduced tumor
growth but also ameliorated cancer associated inflam-
mation via inhibiting inflammatory cell STAT3 activa-
tion. These finding indicates that monocyte-dervied
STAT3 is a possible new therapeutic target for HCC.
The presence of inflammatory cells including mono-
cytes in the tumor microenvironment has been widely
reported. The function of these cancer associated inflam-
matory cells is complicated and generally viewed as both
beneficial as anti-tumorogenic and tumor promoting in
regards of the immune response. In the present study, we
observed monocytes infiltrating the peritumoral and
intratumoral area of HCC and the associated STAT3
activation, which was statistically significant and asso-
ciated with poor prognosis in these cells is prominent. At
present, the underlying mechanisms for these inflamma-
tory cells are not well known. Previous studies indicate
that the immunosuppressive response, angiogenic factors
and tumor-promoting chemokines induced by infiltrating
inflammatory cells contribute to tumor growth and
metastasis [10]. Recently, IL-17 and IL-21, synthesized by
immune cells has been shown to promote tumor devel-
opment in inflammation-associated cancers [37,38]
Our results, along with the study in other different types
of cancer [7,10-12], indicate the existence of an association
between STAT3 activation in monocytes and poor prog-
nosis. (Figure 1). This observation in clinical setting sug-
gests that tumor-infiltrating monocytes STAT3 expression
m a yh a v eap r o t u m o r a lf u n c t i o n .A l t h o u g hm o s to f
patients in our study have the history of HBV infection, it
is very difficult to clarify the relationship between natural
history of the HBV infection and STAT3 activation. HCC
is the very late stage of severe liver disease and survival
time of the patients is limited. One interesting finding
showed that STAT3 expression and phosphorylation was
not altered in HCV-fibrosis patients and alcoholic cirrho-
sis, while STAT3-DNA binding was markedly suppressed
in all alcoholic and most HCV fibrosis patients when com-
pared with that in normal healthy livers[39,40]. Elucidating
the roles STAT3 in HBV infection and HBV inducing neo-
plastic transformation will shed light on the molecular
basis of liver cancer and may suggest therapeutic strategies
for this severe disease.
IL-6 is a multifunctional cytokine which is known to
affect proliferation, apoptosis and angiogenesis in cancer
[41]. In liver disease, clinical data also indicate that serum
IL-6 concentrations are elevated in patients with chronic
liver inflammation, and steatohepatitis as well as in
patients with HCC [42]. Notably, men are about three to
five times more likely to develop HCC than women [43].
Similar gender disparity was also observed in a murine
model of HCC induced by diethylnitrosamine (DEN). It is
believed that higher serum levels of IL-6 in male mice
contribute to the increased susceptibility to DEN-induced
liver cancer in these mice compared with female mice
[19]. Since IL-6 can strongly activate the STAT3 signaling
pathway, it is reasonable to expect STAT3 also plays a cri-
tical role in HCC development. Indeed, a previous study
has already reported constitutively activated STAT3 in
human liver tumor tissues [22]. Consistent with this study,
we also found STAT3 activation in tumor cell. Moreover,
we observed STAT3 activation in infiltrated monocytes
adjacent to tumor tissue (Figure 1a). Activated STAT3 in
monocytes are positively correlted with a poor prognosis
(Figure 1b). Previous study showed that, strong STAT3
immunostaining was observed in the cytoplasm of HCC
tissues, while pY705STAT3 immunostaining was observed
Figure 6 NSC 74859 ameliorated cancer-associated
inflammation in DEN-induced HCC mice. mRNA in T and NT
tissues were analyzed by real-time PCR (n = 4).
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chemical inhibitors or siRNA induced liver cancer cell
apoptosis and cell cycle arrest in vivo, and inhibited
growth of transplanted liver cancer cells in vivo [22]. In
this study, we observed that altered p-STAT3 expression
was significantly and positively correlated with the histolo-
gical grading and intratumor microvessel density in HCC.
Interestingly, recent studies suggest that STAT3 activation
is also implicated in HCV- and obesity-mediated hepato-
carcinogenesis [35,36]. Another important evidence for
the role of STAT3 in liver cancer development is that con-
stitutively activated STAT3 is detected in cancer stem cells
from HCC and likely contributes to liver cancer stem cell
proliferation and survival [44]. Collectively, Activation of
STAT3 in cancer cells plays an important role in liver
tumorigenesis.
The oncogenic role of constitutively activated STAT3 is
driven through the up-regulation of cell survival proteins
(Bcl-xl, Bcl-2), cell cycle regulators (c-Myc, cyclin D)
[12,30-32], anti-oxidant genes (Mn-SOD, ferritin, catalse),
and tissue repair genes (Reg b,R e gg, Tff3) [31,45,46]. Our
study also showed that STAT3 inhibitor treatment down-
regulated cell proliferation-related gene expression.
Recently, a key novel molecule, sphingosine-1-phosphate
receptor-1 (S1PR1) that is induced by STAT3, has been
discovered to play an important role in inducing persistent
STAT3 activation in tumor cells and in the tumor micro-
environment [47].
Besides promoting tumor cell proliferation and inhibiting
cell apoptosis [31,48,49], the activation of STAT3 in cancer
cell has also shown to increase the capacity of tumor to
evade the immune system, by inhibiting the maturation of
dendritic cells and suppressing the immune response
[7,50]. Overexpression of STAT3 in tumor cells can recruit
tumor-infiltrating hematopoietic cells by producing che-
motactic factors, resulting in infiltrating inflammatory
immune cells and subsequently STAT3 activation in
immune cells. The interplay of STAT3 in cancer cells and
immune cells in tumor microenvironment is very complex
and remains elusive. Previous studies show that the persis-
tent activation of STAT3 in immune/inflammatory cells is
also very important in the control of tumor promotion and
progression through tumor-promoting inflammation and
suppressing anti-tumor immunity[51-53]. Our study
demonstrates that in vivo monocytes can promote liver
cancer cell proliferation via IL-6/STAT3 signaling pathway
(Figure 2). This is direct evidence to demonstrate STAT3
in monocytes can broadly and profoundly affect tumor
growth via stimulation of tumor cell survival and prolifera-
tion. In vivo, STAT3 inhibitors can also decrease cancer-
associated inflammation, suggesting that targeting leuko-
cyte STAT3 in the tumor microenvironment may be a
therapeutic option that will be applicable in the future.
However, these results are in contrast to a previous report
[54]. In this report, the authors indicate that the deletion of
STAT3 in myeloid cells, including leukocytes, enhances
inflammation in concanavalin A-induced hepatitis. These
results suggest that STAT3 inhibition in immune cells
leads to enhanced inflammation. These conflicting observa-
tions indicate the complexity of molecular mechanisms
underlying liver inflammation and cancer. Decreased
tumor-associated inflammation induced by STAT3 inhibi-
tor may be a secondary response after the inhibition of
STAT3 in tumor cells. Future studies will determine why
STAT3 inhibitors decrease tumor-associated inflammation
while enhancing necrotic-associated inflammation.
Conclusions
Our study clearly suggests constitutively activated
STAT3 monocytes promoting liver tumorigenesis in
clinical patients and animal experiments. STAT3 in
tumor infiltrating monocytes also is an attractive target
for cancer therapy.
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